Flatiron Health Partners with NRG Oncology to Enhance Clinical Trial Data Capture

Flatiron Health, a Roche Group affiliate specializing in health technology, has announced a significant partnership with NRG Oncology to deploy its innovative clinical data capture tool across a network of cancer research sites. This collaboration aims to streamline data collection processes and accelerate study timelines in oncology clinical trials.

Expanding Reach in Clinical Research

Flatiron Health's Clinical Pipe, a tool designed to capture and transfer data by connecting electronic health records to electronic data capture systems, will be implemented in a multicenter clinical trial conducted by NRG Oncology. NRG Oncology, a research consortium within the National Clinical Trials Network at the National Cancer Institute, boasts a network of over 1,300 sites.

The partnership's primary objective is to enhance efficiency and reduce the time and effort required for study data capture. Alex Deyle, Flatiron's general manager of clinical research, emphasized the potential impact: "By putting our cutting-edge technology in the hands of more research teams, Flatiron and NRG will enhance our ongoing efforts to improve efficiency and reduce time and effort of study data capture, ultimately accelerating evidence generation and improvements in care for people with cancer."

Proven Efficiency in Data Transfer

Recent research published in ESMO Real World Data and Digital Oncology in February demonstrated the efficiency of Flatiron's Clinical Pipe tool. The study found that users could transfer patient data into case reports and submit them in an average of just 37 seconds, highlighting the potential for significant time savings in clinical trial processes.

Industry Partnerships and Future Outlook

This latest collaboration adds to Flatiron Health's growing list of partnerships within the pharmaceutical and healthcare sectors. In 2023, the company secured a deal with Sanofi to implement the Clinical Pipe tool in its oncology sites. Additionally, Flatiron expanded its technology's reach to the Association of Cancer Care Centers' network of community cancer centers in May of the previous year.

While Flatiron Health continues to make strides in health technology, recent reports suggest that Roche, which acquired the company for $1.9 billion in 2018, may be considering selling the formerly Alphabet-backed firm. As the landscape of health technology and clinical research continues to evolve, partnerships like the one between Flatiron Health and NRG Oncology underscore the ongoing importance of innovative data solutions in advancing cancer research and patient care.